Tag: ctDNA

Bioinformatics Specialist I — Cancer Computational Biology —- Cancer Center in Boston, MA for MGH Institute of Health Professions

Details Posted: 05-Jun-22 Location: Boston, Massachusetts Salary: Unpaid Internal Number: 3190190-3499_1654275737 URLs: www.massgeneral.org/cancer-center/clinical-trials-and-research/center-for-cancer-research/investigators/rheinbay-lab www.massgeneral.org/cancer-center/clinical-trials-and-research/center-for-cancer-research/investigators/lawrence-lab Unique opportunity to join an interdisciplinary team bridging the Harvard Medical School, the Massachusetts General Hospital, and the Broad Institute of Harvard and MIT. The Rheinbay Lab and Lawrence Lab at the Massachusetts General Hospital Cancer…

Continue Reading Bioinformatics Specialist I — Cancer Computational Biology —- Cancer Center in Boston, MA for MGH Institute of Health Professions

cfDNA-Based NGS IG Analysis in Lymphoma

Circulating cell-free DNA (cfDNA) is fragmented extracellular DNA, which is released from apoptotic and necrotic cells in small fragments of <200 bp [1]. cfDNA is typically isolated from the blood stream; however, it is also possible to detect cfDNA in other biological fluids such as urine or cerebrospinal fluid [2, 3,…

Continue Reading cfDNA-Based NGS IG Analysis in Lymphoma

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

New Products Posted to GenomeWeb: Myriad Genetics, Invitae, Seqster, More

Myriad Genetics Precise Oncology Solutions  Myriad Genetics announced the launch of Precise Oncology Solutions, a new service through which oncologists can order its BRACAnalysis CDx and MyChoice CDx; its MyRisk Hereditary Cancer Test; and the Precise Tumor Molecular Profile Test, which is performed at a CLIA-certified lab operated by Intermountain…

Continue Reading New Products Posted to GenomeWeb: Myriad Genetics, Invitae, Seqster, More

A pilot study of the use of dynamic cfDNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas

The diagnosis of vitreoretinal lymphoma (VRL), a rare subtype of primary central nervous system lymphoma (PCNSL), is challenging. We aimed to investigate the mutational landscape of VRL by sequencing circulating tumor DNA (ctDNA) from aqueous humor (AH) and/or vitreous fluid (VF), as well as the application of ctDNA sequencing to…

Continue Reading A pilot study of the use of dynamic cfDNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

The Evolving Treatment Landscape of Cholangiocarcinoma

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations. The advances in the understanding and characterization of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), and genomic profiling over the past decade have led to a rapid expansion of available treatment…

Continue Reading The Evolving Treatment Landscape of Cholangiocarcinoma

Next Generation Sequencing Industry to Cross $34.8 Billion by 2027

DUBLIN, Dec. 8, 2021 /PRNewswire/ — The “Next Generation Sequencing Market, Global Forecast, Impact of COVID-19, Industry Trends, Growth, Opportunity By Types of Test, Company Analysis” report has been added to ResearchAndMarkets.com‘s offering. According to the report, the Global Next Generation Sequencing Market will reach US$ 34.8 Billion by 2027….

Continue Reading Next Generation Sequencing Industry to Cross $34.8 Billion by 2027

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

Amgen Is Recruiting A Principal Scientist

Employer Amgen Location South San Francisco, CA Posted Sep 20, 2021 Ref R-121973 Discipline Science/R&D, Biology, Biotechnology Hotbed  Biotech Bay, Ideal Employer Required Education Bachelors Degree Position Type Full time Amgen is a leading global biotechnology company, with a mission to serve patients around the world. The Clinical Biomarkers &…

Continue Reading Amgen Is Recruiting A Principal Scientist

New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…

Continue Reading New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

“Our longstanding relationship with the NSABP, through our work to develop and validate the Oncotype DX Breast Recurrence Score® and Colon Recurrence Score® tests, represents a remarkable collaboration between academic and industry partners. This relationship has fueled major advancements in understanding the role of molecular profiling in breast and colon…

Continue Reading Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

Can a Blood Test Predict Lymphoma Relapse?

With next-generation sequencing, clinicians can test the blood plasma of patients with large B-cell lymphoma to see the amount of cancer DNA – known as circulating tumor DNA (ctDNA) – that exists, thus predicting their risk of relapse. For over a decade, blood samples were telling of acute lymphoblastic leukemia…

Continue Reading Can a Blood Test Predict Lymphoma Relapse?

Gene mutation analysis in papillary thyroid carcinoma

Introduction Thyroid tumors are the most common malignant tumors of the endocrine system, and their incidence has been increasing in the recent decades. Currently, there are some target drugs that can effectively treat PTC, and next-generation sequencing (NGS) can be used for targeted therapy. In order to make better informed…

Continue Reading Gene mutation analysis in papillary thyroid carcinoma

Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

This article was originally published here Clin Genitourin Cancer. 2021 Jul 31:S1558-7673(21)00151-8. doi: 10.1016/j.clgc.2021.07.012. Online ahead of print. ABSTRACT BACKGROUND: There has been considerable interest in ctDNA next generation sequencing platforms to assess genomic alterations in mCRPC given its accessibility and identification of temporal genomic data. PATIENTSAND METHODS: In this…

Continue Reading Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

pughlab/inspire-genomics: Pan-cancer analysis of genomic and immune landscape profiles of metastatic solid tumors treated with pembrolizumab

Contents Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist to show the relationship between ctDNA dynamics and tumor genome and immune microenvironment in patients receiving ICB. Here, we present…

Continue Reading pughlab/inspire-genomics: Pan-cancer analysis of genomic and immune landscape profiles of metastatic solid tumors treated with pembrolizumab

ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

“…ctDNA may be more comprehensive representation of the tumor mutations of an individual patient,” the authors explained. “Longitudinal ctDNA analysis can also provide a molecular profile of how a tumor evolves and changes over time in response to chemotherapy.” They evaluated how the results of ctDNA analysis were associated with…

Continue Reading ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

Bioinformatics Scientist/Senior Scientist – Torre

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the utilization of unexploited insights in immunology. The company was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries. We are located in the San Francisco bay…

Continue Reading Bioinformatics Scientist/Senior Scientist – Torre